Hybribio Biotech secures new patent amid extensive payment disputes

Guangdong Hybribio Biotech and its subsidiaries announced in October 2025 the acquisition of an invention patent for a "microfluidic chip for live cell sorting." This patent is crucial for the company's "development of cervical exfoliated cell sorting devices," aiming to enhance sorting accuracy and prevent cell damage. The technology has already received patent authorization in mainland China, Hong Kong, Macau, the U.S., South Korea, and Australia.

Concurrently, Hybribio Biotech reported 102 cumulative litigation and arbitration cases over the past 12 months, totaling RMB 415.86 million, representing 10.12% of its net assets attributable to shareholders. The majority of these cases (69 cases, RMB 357.17 million) involve the company as the plaintiff, primarily seeking overdue payments from public health commissions and medical institutions for goods or services rendered between 2020 and 2022. The remaining 33 cases (RMB 58.70 million) name the company as the defendant.

Hybribio Biotech aims to reduce the negative impact of these receivables on its performance and cash flow by pursuing legal action. The company stated that the current litigation is not expected to significantly affect its present operations but will enhance its intellectual property system and product offerings. The financial impact will depend on the outcomes of these cases and will be finalized after external audits.